The authors examined the relation of hypertension, use of diuretics, and use of antihypertensive medications to the nsk of fatal renal cell cancer in a prospective cohort study of 998,904 adult Americans followed for 7 years (1982)(1983)(1984)(1985)(1986)(1987)(1988)(1989). Analysis included 335 renal cell cancer deaths (123 in women and 212 in men). Cox proportional hazards modeling was used to calculate rate ratios. Increased rate ratios were present for cigarette smoking in men and for elevated body mass index in both sexes. Significantly increased agematched rate ratios, independent of smoking and body mass index, were present for hypertension, use of diuretics, and use of hypertension medications, but only for women. Multivariate testing confined these nsks to hypertensive women who were using hypertension medications alone (rate ratio = 2.2, 95% confidence interval 1.4-3.5) or with diuretics (rate ratio = 2.5, 95% confidence interval 1.5-4 3). Risk was not significantly increased for either men or women who had untreated hypertension or who used diuretics alone with or without hypertension. These findings partly support those of earlier studies suggesting that medications related to treatment of hypertension, or the seventy of hypertension itself, may contribute to the etiology of renal cell cancer. Am J Epidemiol 1997;145:607-13. antihypertensive agents; diuretics; hypertension; kidney; kidney neoplasms At least 16 epidemiologic studies have been conducted to date which in different ways addressed the possibility that hypertension, diuretics, and other medications used to treat hypertension may increase the risk of renal cell cancer separately or in combination (1-17). The interdependent nature of these risk variables has made results difficult to interpret. Study designs have varied ((12 were case-control studies (1-4, 7, 9, 10, 12-17) and four were cohort studies (5, 6, 8, 11)), as have the nature and sources of data concerning histories of illness and medication use. Among 14 studies that recorded data on history of hypertension, 10 found a statistically significant association between hypertension and increased risk of renal cell cancer (1, 5-7, 10, 13-17), although the association did not always appear in both sexes or after medication use was taken into account. Diuretic use was studied in 12 instances; significant associations, especially in women, were seen in 10 (2, 3, 8-12, 14, 16, 17), with three showing rate ratios of 4.0 or greater (3, 5, 12) . In some studies, the link to diuretic use Recerved for publication April 15,1996, and in final form October 28, 1996. 1 Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
At least 16 epidemiologic studies have been conducted to date which in different ways addressed the possibility that hypertension, diuretics, and other medications used to treat hypertension may increase the risk of renal cell cancer separately or in combination (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . The interdependent nature of these risk variables has made results difficult to interpret. Study designs have varied ((12 were case-control studies (1-4, 7, 9, 10, 12-17) and four were cohort studies (5, 6, 8, 11) ), as have the nature and sources of data concerning histories of illness and medication use. Among 14 studies that recorded data on history of hypertension, 10 found a statistically significant association between hypertension and increased risk of renal cell cancer (1, 5-7, 10, 13-17) , although the association did not always appear in both sexes or after medication use was taken into account. Diuretic use was studied in 12 instances; significant associations, especially in women, were seen in 10 (2, 3, 8-12, 14, 16, 17) , with three showing rate ratios of 4.0 or greater (3, 5, 12) . In some studies, the link to diuretic use appeared to account for the hypertension association and in fact was present for diuretic use in the absence of hypertension (2, 3, 16) . In five studies (5, 7, 14, 16, 17) , the use of nondiuretic hypertension medications was examined, and in each instance a significant association with increased renal cell cancer risk was found. The finding seemed to be independent of hypertension status and not limited to particular drugs. No clear evidence of a dose-response relationship was found for any medication, and only suggestive information on duration of medication use was found.
These accumulated data provide an unclear picture in which use of diuretics, and perhaps particular nondiuretic hypertension medications, may cause a moderate increase in the risk of renal cell cancer, especially among women, but in which hypertension by itself may or may not increase risk. To examine these questions further, we analyzed renal cell cancer mortality data accrued over 7 years of follow-up in a large prospective cohort study.
MATERIALS AND METHODS
Study subjects were drawn from Cancer Prevention Study II, a prospective mortality study of approximately 1.2 million adult Americans (aged ^30 years at entry) begun in 1982 by the American Cancer Society. Participants were recruited by more than 77,000 American Cancer Society volunteers in all 50 states, the District of Columbia, and Puerto Rico. At entry into Cancer Prevention Study n, subjects completed a confidential four-page questionnaire which sought information on demographic characteristics, personal and familial history of illness, and a wide range of potential risk factors related to cancer. Mortality follow-up was conducted by personal volunteer contacts at 2-year intervals through August of 1988 and by computer linkage to the National Death Index through December 1989 (18 Information collected at study entry indicated the presence or absence of certain specific disorders and (notably for this study) personal history of high blood pressure, kidney disease, kidney stones, bladder disease, and cancer, as well as family history of renal cancer (table 2) . Diseases other than cancer were noted on a checklist of conditions ever diagnosed by a doctor. Information on use of medications-particularly "blood pressure pills" (not otherwise specified), diuretics ("water pills"), and Tylenol (McNeil Consumer Products, Fort Washington, Pennsylvania) (acetaminophen)-was obtained in response to the question, "How many times in the past month have you used the following, and how long have you used them?" Other questionnaire information used in analysis included educational level, history of cigarette smoking (never, current, and former), body mass index (weight (kg)/ height (m)
2 ), race (white/nonwhite), and occupational exposure to asbestos.
All variables were considered dichotomous (yes/no, any/none) except cigarette smoking, body mass index, and education. Body mass index was categorized on the basis of percentage cutpoints used in the Second National Health and Nutrition Examination Survey (20). For men, the categories were <20.7, 20.7-24.6, 24.7-27.7, 27.8-31.0, and >31.1, and for women they were <19.1, 19.1-21.9, 22.0-27.2, 27.3-32.2, and S32.3. The second category was used as the referent in regression models. Education was categorized as college graduation (referent), some college/vocational school, high school graduation, and less than high school graduation.
Missing values for body mass index (2.1 percent of the analytic cohort) were assigned on the basis of average values in the cohort for a specific age and sex. Persons missing any data regarding medical history were considered free of that particular disease. Persons missing information on smoking status (5.3 percent) were assigned to a separate smoking category. Persons • Weight (kg)/height (m)J. t Cutpoints were based on data from the Second National Health and Nutrition Examination Survey (20).
missing data on education (1.2 percent) were assigned to the most common category, high school graduate.
To categorize medication use, we evaluated answers in terms of both amount and duration. Where answers were unclear, we assigned values based on patterns of response given for other medications, having noted considerable uniformity in the manner in which any given person completed the questionnaire. Cox proportional hazards modeling (21) was used to calculate rate ratios for diuretic and hypertension medication use while adjusting for the effects of other potential risk factors. Regression models were matched on age at study entry as a continuous variable. The time variable used in Cox regression was duration of follow-up, and proportional hazards assumptions for exposure variables were tested by considering interaction terms between follow-up time and exposure.
RESULTS
Data on various analytic variables and renal cell cancer deaths are given in table 2. The mean age at death of renal cell cancer patients at study entry (61-62 years) was slightly higher than that for the cohort as a whole (56-57 years). Frequencies of increased body mass index and lower educational levels were somewhat greater among renal cell cancer deaths than in the analytic cohort, especially in women. History of hypertension, use of diuretics, and use of antihypertensive medications were all clearly increased among persons who died of renal cell cancer, more so for women than for men. Use of acetaminophen was not increased among renal cell cancer deaths.
Renal cell cancer risk was significantly increased with history of hypertension in women but not in men, a pattern that also held for use of either diuretics or hypertension medications (table 3) . Risks were significantly increased for both current and former cigarette smoking in men; in female smokers, levels of risk were lower and were not significantly increased. Rate ratios were increased for elevated body mass index in both sexes. Ratios rose with increasing body mass index above the referent level and became statistically significant in the highest two quintiles; risk increases were distinctly greater in women than in men. A history of urologic disease was associated with increased risk in men but not in women, while risk was nonsignificantly increased among women with a family history of renal cancer. Risk was not increased materially in either sex in relation to acetaminophen use. Table 4 shows age-adjusted and multivariate rate ratios for various mutually exclusive categories of hypertension, diuretic use, and hypertension medication use. In no instance was risk increased in the presence of hypertension alone, especially under conditions of multivariate analysis. However, since few persons reported hypertension without some form of medication use, these results were based on small numbers, especially in women. There was no statistically significant risk increase for diuretic use in either sex, with or without hypertension. Observations regarding diuretic use alone in the presence of hypertension were limited by small numbers of deaths. In women, but not in men, risk was significantly increased for use of hypertension medications, regardless of whether diuretic use was also present. All persons reporting use of hypertension medications were considered to have a history of hypertension.
No tendency for women's renal cell cancer risk to rise with increasing amounts or durations of hypertension medication use was observed (table 5) . In addition, the positive association between hypertension medication use and renal cell cancer risk in women was not modified by current cigarette smoking or body mass index.
DISCUSSION
The results of this analysis provide only weak support for the suggestion from earlier epidemiologic studies that use of diuretics increases risk for renal cell cancer. If an association does exist, our data suggest that it is more likely to affect women than men (table  3) and that it may be independent of hypertension status. Our data also suggest, however, that either use of hypertension medications or the severity of hypertension itself (as reflected in the need for medication) may be a significant risk factor, although again more for women than for men (table 4). Although we cannot rule out the possibility that the lack of increased risk for hypertensive persons who were not using medica- * Rate ratios were estimated using Cox proportional hazards modeling with matching on age at study entry as a continuous variable.
t Cl, confidence interval. $ All persons using antahypertensive medication also reported a history of hypertension. § Weight (kg)/height (m)*. H Cutpoints were based on data from the Second National Health and Nutrition Examination Survey (20). tion may merely reflect early or mild disease and that use of either form of medication may indicate more serious disease, our findings do suggest that the increased risk observed for persons using hypertension medications may represent a true association with medication use alone. The finding, however, is relatively weak, since rate ratios were no higher than approximately 2.5. No information was available with which to identify specific dosage levels or specific diuretic or antihypertensive drugs, given the limited nature of data collected in the study. It is likely that some degree of misclassification may exist between use of diuretics and use of antihypertensive medications. As recorded, however, the data suggest similar risk tendencies for each type of drug, i.e., greater risk in women than in men and risk influences which are probably independent of hypertension status itself. Again, however, it is difficult to disentangle the possible effects of these medications from a possible severity-related influence of underlying hypertension. As expected from studies conducted elsewhere (22, 23) , renal cell cancer risks were clearly increased both for cigarette smoking and for elevated body mass index. In the case of smoking, this heightened risk was especially evident in men, and in the case of body mass index, especially in women. The tendency for particular renal cell cancer rate ratios to differ between the sexes, especially as they may reflect nonsmoking risks in women (witness the findings here for body mass index, hypertension medications, and possible diuretics), suggests the possible existence of fundamental sex-related etiologic differences and therefore emphasizes the continuing importance of considering renal cell cancer risk profiles in each sex separately (3, 9, 12, 14) .
No relation was seen with use of acetaminophen. This finding agrees with that of other studies (9, 24) . The possibility of an association, however, continues to be of interest, since not all studies are in agreement (25, 26) and since acetaminophen is the major metabolite of phenacetin, a well-recognized risk factor for cancer of the renal pelvis and possibly for renal cell cancer as well (1, (27) (28) (29) .
Being based on a prospective study, our analysis avoided some measure of observer bias by having the advantage of using risk factor information that was probably acquired a year or more before illness diagnosis. The massive size of the study, however, precluded the use of extensive questionnaires, and hence made it impossible to obtain much detail concerning medication usage. While the relative rareness of renal cell cancer necessarily limited the size of the study, a sufficient number of cases were identified to attain a reasonable level of statistical power. Since the study was li mi ted to fatal outcomes and included only those fatal renal cell cancer cases recorded as such on death certificates, it is likely to have encompassed somewhat less than half of all diagnosed renal cell cancer cases in the Cancer Prevention Study II cohort. We know of no reason, however, to think that fatal and nonfatal renal cell cancer cases might differ substantially in their risk factor profiles. This thought seems to be supported by the general similarities between our findings in this mortality-based study and those of earlier investigations based in incident cases (3, 7, 9, 10, (12) (13) (14) .
If hypertension itself, or the medications used in its treatment, does in fact increase renal cell cancer risk, the mechanisms by which such a risk may operate are unclear. Limited experimental research suggests that particular hypertension medications (specifically furosemide and hydrochlorothiazide) may increase renal tumor occurrence in rats (10, (12) (13) (14) 30) . With regard to humans, recently published articles have suggested that calcium channel blockers, a commonly used form of hypertension treatment, may be associated with a general increase in human cancers (renal cell cancer included), a possible mechanism being interference with cellular apoptosis (31, 32) . In the interim, the results of our study provide only tentative support for the general idea that hypertension and its medications can result in heightened renal cell cancer occurrence.
